# Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

> **NCT03396497** · PHASE1 · UNKNOWN · sponsor: **Lycera Corp.** · enrollment: 17 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** LYC-55716
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03396497
- **Lead sponsor:** Lycera Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-03
- **Primary completion:** 2019-10-20
- **Final completion:** 2019-10-20
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03396497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03396497, "Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03396497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*